^
Association details:
| Biomarker: | RET rearrangement |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
09/15/2020
Excerpt:
The Panel recommends selpercatinib, pralsetinib, cabozantinib, or vandetanib (category 2B for vandetanib) as subsequent therapy options for select patients with RET rearrangement positive metastatic NSCLC who have not previously received these agents…
Source:
Title:
Phase II Study With Cabozantinib in Patients With RET Positive NSCLC
Excerpt:
...RET gene rearrangement by local laboratory analysis with an approved standard method (FISH or Next Generation Sequencing Panel)....
Trial ID:
Source:
Title:
Phase II study with Cabozantinib in patients with RET positive NSCLC Studio di fase II con Cabozantinib in pazienti con NSCLC RET positivo
Excerpt:
...RET gene rearrangement by local laboratory analysis with an approved standard method (FISH or Next Generation Sequencing Panel). ...
Trial ID:
